Apparent mineralocorticoid excess and the long term treatment of genetic hypertension

详细信息    查看全文

• 作者：Maryam Razzaghy-Azar^a ; ^b ; Mabel Yau^c ; ^{mabel.yau@mssm.edu} ; Ahmed Khattab^c ; Maria I. New^c
• 关键词：Low renin hypertension ; 11β-Hydroxysteroid dehydrogenase type 2 ; Spironolactone
• 刊名：The Journal of Steroid Biochemistry and Molecular Biology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：165
• 期：part_PA
• 页码：145-150
• 全文大小：1170 K
• 卷排序：165

文摘

AME is a hypertensive disorder owing to 11ßHSD2 deficiency. More than 40 mutations in the HSD11B2 gene causing AME have been identified. Chronic hypertension in AME leads to the early development of end organ damage. Spironolactone treatment of AME normalizes blood pressure and improves growth. Renal transplantation of patients with AME and renal failure led to cure of AME.